Sorafenib Standard Dosing Regimen — Competitive Intelligence Brief

Sorafenib Standard Dosing Regimen (Sorafenib Standard Dosing Regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-kinase inhibitor. Area: Oncology.

marketed Multi-kinase inhibitor BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT Oncology Small molecule

Target snapshot

Sorafenib Standard Dosing Regimen (Sorafenib Standard Dosing Regimen) — University of Florida. Sorafenib is a multi-kinase inhibitor that blocks several receptor tyrosine kinases involved in tumor cell proliferation and angiogenesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sorafenib Standard Dosing Regimen TARGET	Sorafenib Standard Dosing Regimen	University of Florida	marketed	Multi-kinase inhibitor	BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib Ramp-Up Regimen	Sorafenib Ramp-Up Regimen	University of Florida	marketed	Multi-kinase inhibitor	BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib (SOR)	Sorafenib (SOR)	The University of Texas Health Science Center at San Antonio	marketed	Multi-kinase inhibitor; RAF/VEGFR/PDGFR inhibitor	RAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib (SORA)	Sorafenib (SORA)	Nanfang Hospital, Southern Medical University	marketed	Multi-kinase inhibitor	RAF, VEGFR-2, VEGFR-3, PDGFR-β
Regorafenib and DIBIRI	Regorafenib and DIBIRI	Sun Yat-sen University	phase 3	Multi-kinase inhibitor (regorafenib) combined with topoisomerase I inhibitor (DIBIRI)	VEGFR, FGFR, KIT, RET, RAF (regorafenib); Topoisomerase I (DIBIRI/irinotecan)
Sorafenib+Pazopanib	Sorafenib+Pazopanib	Technical University of Munich	phase 3	multi-kinase inhibitor	RAF, VEGFR, PDGFR
Lenvatinib, sintilimab plus TACE	Lenvatinib, sintilimab plus TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-kinase inhibitor + PD-1 inhibitor + locoregional chemotherapy	FGFR, VEGFR, RET, KIT (lenvatinib); PD-1 (sintilimab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-kinase inhibitor class)

1. University of Florida · 2 drugs in this class
2. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
3. Nanfang Hospital, Southern Medical University · 1 drug in this class
4. Stephen Chan Lam · 1 drug in this class
5. Sun Yat-sen University · 1 drug in this class